{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Espy N"],"funding":["National Institute of Allergy and Infectious Diseases","National Center for Research Resources","Center for AIDS Research, Duke University"],"pagination":["e0002037"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10249892"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["3(6)"],"pubmed_abstract":["Candidate HIV vaccines are designed to induce antibodies to various components of the HIV virus. An unintended result of these antibodies is that they may also be detected by commercial HIV diagnostic kits designed to detect an immune response to HIV acquisition. This phenomenon is known as Vaccine-Induced Seropositivity/Reactivity (VISP/R). In order to identify the vaccine characteristics associated with VISP/R, we collated the VISP/R results from 8,155 participants from 75 phase 1/2 studies and estimated the odds of VISP/R by multivariable logistic regression and 10-year estimated probability of persistence in relation to vaccine platform, HIV gag and envelope (env) gene inserts, and protein boost. Recipients of viral vectors, protein boosts, and combinations of DNA and viral-vectored va"],"journal":["PLOS global public health"],"pubmed_title":["Cross-protocol assessment of induction and durability of VISP/R in HIV preventive vaccine trial participants."],"pmcid":["PMC10249892"],"funding_grant_id":["UM1 AI069412","UL1 RR025758","UM1 AI068635","UM1 AI068614","P30 AI064518","UM1 AI068618"],"pubmed_authors":["Lakshminarayanan B","Hural J","Espy N","Grant S","Goecker E","Andriesen J","Han X","Stirewalt M","Seaton KE","Huang Y","Kwara E","Walsh SR","Tomaras GD","McElrath J"],"additional_accession":[]},"is_claimable":false,"name":"Cross-protocol assessment of induction and durability of VISP/R in HIV preventive vaccine trial participants.","description":"Candidate HIV vaccines are designed to induce antibodies to various components of the HIV virus. An unintended result of these antibodies is that they may also be detected by commercial HIV diagnostic kits designed to detect an immune response to HIV acquisition. This phenomenon is known as Vaccine-Induced Seropositivity/Reactivity (VISP/R). In order to identify the vaccine characteristics associated with VISP/R, we collated the VISP/R results from 8,155 participants from 75 phase 1/2 studies and estimated the odds of VISP/R by multivariable logistic regression and 10-year estimated probability of persistence in relation to vaccine platform, HIV gag and envelope (env) gene inserts, and protein boost. Recipients of viral vectors, protein boosts, and combinations of DNA and viral-vectored va","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023","modification":"2025-04-27T02:16:27.724Z","creation":"2025-04-06T18:32:59.617Z"},"accession":"S-EPMC10249892","cross_references":{"pubmed":["37289667"],"doi":["10.1371/journal.pgph.0002037"]}}